Develops antibody therapies for treating inflammatory diseases and oncology indications.
XBiotech Inc., a dynamic biopharmaceutical company based in Austin, Texas, specializes in the discovery, development, and commercialization of True Human monoclonal antibodies. Our innovative approach targets a wide range of diseases, focusing on both inflammatory and infectious conditions. Our robust pipeline includes interleukin-1 alpha therapies designed to address significant medical challenges such as cancer, stroke, heart attack, and arthritis. These therapies play a critical role in mediating tissue breakdown, angiogenesis, blood clot formation, muscle wasting, malaise, and inflammation.
Amidst current global challenges, XBiotech Inc. is actively pursuing True Human COVID-19 therapy to combat the mutating strains of the virus. This initiative underscores our commitment to leveraging cutting-edge science to develop effective treatments for emerging infectious diseases. Founded in 2005, our company continues to push the boundaries of biopharmaceutical innovation, striving to improve patient outcomes and advance healthcare globally.
Headquartered in Austin, Texas, XBiotech Inc. operates at the forefront of monoclonal antibody research and development. Through our dedication to scientific excellence and strategic focus on addressing unmet medical needs, we are poised to make significant contributions to the field of biopharmaceuticals.